NegGram (Nalidixic Acid) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Neggram

Urinary Tract Infection (UTI In Adults) »

Urinary tract infection (UTI) facts

Urinary tract infections (UTIs) are infections of the urethra, bladder, ureters, or the kidneys, which comprise the urinary tract.
E. coli bacteria cause the majority of UTIs, but many other bacteria, fungi, and parasites may also cause UTIs.
Females have a higher risk for UTIs than most males, probably because of their anatomy; other risk factors for UTIs include any condition that may impede urine flow (e.g., enlarged prostate, congenital urinary tract abnormalities, and inflammation). Patients with catheters or those who undergo urinary surgery and men with enlarged prostates are at higher risk for UTIs.
Symptoms and signs of UTI vary somewhat depending on sex, age, and the area of the urinary tract that is infected; some unique symptoms develop depending on the infecting agent.
UTIs are diagnosed usually by isolating and identifying the urinary pathogen from the patient; there a...

Read the Urinary Tract Infection (UTI In Adults) article »

NegGram

Take the UTI Quiz

Urinary Tract Infection (UTI) Slideshow Pictures

Urinary Incontinence in Women Slideshow Pictures

font size

OVERDOSE

Manifestations

Toxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.

Treatment

Reactions are short-lived (two to three hours) because the drug is rapidly excreted. If absorption has occurred, increased fluid administration is advisable and supportive measures such as oxygen and means of artificial respiration should be available. Although anticonvulsant therapy has not been used in the few instances of overdosage reported, it may be indicated in a severe case.

CONTRAINDICATIONS

NegGram is contraindicated in patients with known hypersensitivity to nalidixic acid or to related compounds, infants less than three months of age, and in patients with porphyria or a history of convulsive disorders. NegGram is contraindicated in patients undergoing concomitant therapy with melphalan or other related cancer chemotherapeutic alkylating agents because of serious gastrointestinal toxicity such as hemorrhagic ulcerative colitis or intestinal necrosis.

Last reviewed on RxList: 6/10/2011
This monograph has been modified to include the generic and brand name in many instances.